Literature DB >> 3816883

Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.

J T Turkka, K K Juujärvi, V V Myllylä.   

Abstract

In order to study the role of the neurotransmitter noradrenaline (NA) and its main brain metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in autonomic failure in Parkinson's disease (PD), an analysis of the relation of cerebrospinal fluid (CSF) NA and MHPG levels and a rating of autonomic nervous system (ANS) impairment was carried out. The mean baseline NA level in CSF of PD patients was 220.0 +/- 110.0 pg/ml, and the mean baseline MHPG level 9.9 +/- 3.9 ng/ml. These levels did not differ from those of age-matched controls. Within the group of patients with PD neither the duration of the disease nor its medication influenced the results. No correlation could be found in patients with PD between the CSF NA levels and the severity of autonomic failure, but a clear correlation was found between the CSF MHPG concentrations and the severity of autonomic failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3816883     DOI: 10.1159/000116308

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  Cerebrospinal fluid catecholamine levels in Japanese encephalitis patients with movement disorders.

Authors:  U K Misra; J Kalita; S Pandey; V K Khanna; G Nagesh Babu
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

3.  Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Authors:  Pamela J McMillan; Sylvia S White; Allyn Franklin; J Lynne Greenup; James B Leverenz; Murray A Raskind; Patricia Szot
Journal:  Brain Res       Date:  2010-12-11       Impact factor: 3.252

4.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

5.  Conceptualization of depression in Parkinson's disease.

Authors:  Jeffrey C Looi; May Matis; Michelle J Ruzich
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

Review 6.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.